Gene expression signature of human HepG2 cell line

Gene

Volumn 518, Issue 2, 2013, Pages 335-345

  Costantini, S ^a   Di Bernardo, G ^b   Cammarota, M ^b   Castello, G ^a   Colonna, G ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Gene expression; HCC; HepG2 cells; Human hepatocytes; Interactomics analysis; RT PCR

Indexed keywords

BRCA1 PROTEIN; INITIATION FACTOR 2; ISOLEUCINE; LEUCINE; SELENIUM BINDING PROTEIN; STAT PROTEIN; VALINE;

ACUTE PHASE RESPONSE; ARTICLE; BREAST CANCER; CELL CYCLE REGULATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEPG2; CHROMOSOME REPLICATION; CONTROLLED STUDY; DNA DAMAGE; DNA RECOMBINATION; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; ENERGY YIELD; FATTY ACID METABOLISM; GENE EXPRESSION; GENETIC ASSOCIATION; GROWTH; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MINERAL METABOLISM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; VITAMIN METABOLISM;

CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; TRANSCRIPTOME; UP-REGULATION;

EID: 84875376150     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.12.106     Document Type: Article

References (62)

1. Amann T., et al. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin. Ther. Targets 2009, 13:1411-1427.
2. Balic A., et al. IL-4R signaling is required to induce IL-10 for the establishment of Th2 dominance. Int. Immunol. 2006, 18:1421-1431.
3. Bansal M.P., et al. DNA sequencing of a mouse liver protein that binds selenium, implications for selenium's mechanism of action in cancer prevention. Carcinogenesis 1990, 11:2071-2073.
4. Benigni A., et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 2009, 119:524-530.
5. Boyault S., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
6. Budhu A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
7. Buettner R., et al. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8:945.
8. Cai M.Y., et al. EZH2 protein, a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 2011, 60:967-976.
9. Capone F., et al. Serum cytokine levels in patients with hepatocellular carcinoma. Eur. Cytokine Netw. 2010, 21:99-104.
10. Castello G., et al. HCV-related hepatocellular carcinoma, from chronic inflammation to cancer. Clin. Immunol. 2010, 134:237-250.
11. Chan K.Y., et al. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Mod. Pathol. 2006, 19:1546-1554.
12. Chang P.W., et al. Isolation characterization and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. J. Cell. Biochem. 1997, 64:217-224.
13. Costantini S., et al. Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis leading to cirrhosis. Eur. Cytokine Netw. 2010, 21:251-256.
14. Costantini S., et al. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One 2012, 7:e39486.
15. Delpuech O., et al. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene 2002, 21:2926-2937.
16. Di Stasio M., et al. A possible predictive marker of progression for hepatocellular carcinoma. Oncol. Lett. 2011, 2:1247-1251.
17. El-Serag H.B., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States, an update. Ann. Intern. Med. 2003, 139:817-823.
18. El-Serag H.B., et al. Hepatocellular carcinoma, epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
19. Erdogmus M., et al. Application of automatic mutation-gene pair extraction to diseases. J. Bioinforma. Comput. Biol. 2007, 5:1261-1275.
20. Ferré P., et al. Hepatic steatosis, a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12:83-92.
21. Freeman W.M., et al. Fundamentals of DNA hybridization arrays for gene expression analysis. Biotechnol. Tech. 2000, 29:1042-1055.
22. Fujii H., et al. Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro. Biochem. Biophys. Res. Commun. 2004, 322:1052-1058.
23. Furge K.A., et al. Comparison of array-based comparative genomic hybridization with gene expression-based regional expression biases to identify genetic abnormalities in hepatocellular carcinoma. BMC Genomics 2005, 6:67.
24. Fusco M., et al. Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur. J. Cancer 2008, 44:847-853.
25. Giannelli G., et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int. J. Cancer 2002, 97:425-431.
26. Guichard C., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44:694-698.
27. Hatzivassiliou G., et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
28. Haung F., et al. Chemokines and hepatocellular carcinoma. World J. Gastroenterol. 2010, 16:1832-1836.
29. Hsu C.N., et al. Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma Genes Online). BMC Bioinforma. 2007, 8:66.
30. Hu K.Q., et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am. J. Gastroenterol. 2004, 99:860-865.
31. Iizuka N., et al. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J. Cancer Res. Clin. Oncol. 2006, 132:473-481.
32. Jemal A., et al. Cancer statistics 2007. CA Cancer J. Clin. 2007, 57:43-66.
33. Johnson P.J. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1999, 14:S32-S36.
34. Jurecic R., et al. Long-distance DD-PCR and cDNA microarrays. Curr. Opin. Microbiol. 2000, 3:316-321.
35. Kusumoto T., et al. Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol. Rep. 2010, 23:917-925.
36. Lee J.S., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
37. Lee L., et al. Liverome, a curated database of liver cancer-related gene signatures with self-contained context information. BMC Genomics 2011, 12:S3.
38. Lee S.T., et al. Context-specific regulation of NF-kB target gene expression by EZH2 in breast cancers. Mol. Cell 2011, 43:798-810.
39. Llovet J.M., et al. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
40. Mahley R.W. Apolipoprotein E, cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
41. Mas V.R., et al. Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation, genes involved in tumor progression. Liver Transpl. 2004, 10:607-620.
42. Matsubara T., et al. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J. Surg. Oncol. 2007, 95:241-249.
43. McGlynn K.A., et al. International trends and patterns of primary liver cancer. Int. J. Cancer 2001, 94:290-296.
44. Meyer R.A., et al. Gene expression in older rats with delayed union of femoral fractures. J. Bone Joint Surg. Am. 2003, 85A:1243-1254.
45. Migita T., et al. ATP citrate lyase, activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 2008, 68:8547-8554.
46. Miranda P.W., et al. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int. J. Mol. Sci. 2011, 12:1009-1029.
47. Monnier J., et al. CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur. J. Cancer 2012, 48:138-148.
48. Parkin D.M., et al. Estimating the world cancer burden, Globocan 2000. Int. J. Cancer 2001, 94:153-156.
49. Patil M.A., et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005, 24:3737-3747.
50. Paz M.F., et al. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003, 22:6335-6345.
51. Rajagopal S., et al. β-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:628-632.
52. Raucci R., et al. Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochim. Biophys. Acta 2011, 1814:513-522.
53. Rubie C., et al. Enhanced expression and clinical significance of CC-chemokine MIP-3 alpha in hepatocellular carcinoma. Scand. J. Immunol. 2006, 63:468-477.
54. Saito S., et al. Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Sci. 2008, 99:2402-2409.
55. Shyu K.G., et al. Mechanism of the inhibitory effect of atorvastatin on leptin expression induced by angiotensin II in cultured human coronary artery smooth muscle cells. Clin. Sci. (Lond.) 2012, 122:33-42.
56. Sistayanarain A., et al. Expression of Aurora-B kinase and phosphorylated histone H3 in hepatocellular carcinoma. Anticancer. Res. 2006, 26:3585-3593.
57. Suzuki A., et al. Identification of melanoma antigens using a serological proteome approach (SERPA). Cancer Genomics Proteomics 2010, 7:17-23.
58. Ueno Y., et al. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J. Gastroenterol. Hepatol. 2009, 24:531-536.
59. Woo H.G., et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14:2056-2064.
60. Xu X.R., et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:15089-15094.
61. Yoon S.Y., et al. Grb2 dominantly associates with dynamin II in human hepatocellular carcinoma HepG2 cells. J. Cell. Biochem. 2001, 84:150-155.
62. Zang F., et al. Identification of Egr1 as the oncostatin M-induced transcription activator that binds to sterol-independent regulatory element of human LDL receptor promoter. J. Lipid Res. 2002, 43:1477-1485.